XT
ELDN icon

XTX Topco’s Eledon Pharmaceuticals ELDN Stock Holding History

XTX Topco’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$204K Sell
66,235
-58,012
-47% -$137K ﹤0.01% 2833
2025
Q4 		$188K Buy
124,247
+111,399
+867% +$265K ﹤0.01% 2429
2025
Q3 		$33.3K Buy
+12,848
New +$37.6K ﹤0.01% 2247

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $712M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
ZP
Zimmer Partners New York $4.15B AUM 14.2% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

XTX Topco's ELDN Position: Q1 2026 in Review

XTX Topco reduced its Eledon Pharmaceuticals (ELDN) stake by 47% in Q1 2026, selling an estimated $137K and leaving 66,235 shares worth $204K. The position accounts for ﹤0.01% of the portfolio, ranked #2833.

XTX Topco first reported a position in ELDN in Q3 2025 and has held it in 3 quarters since. 121 funds tracked by Wall St. Rank hold ELDN as of Q1 2026.

  • XTX Topco held 66,235 shares of Eledon Pharmaceuticals worth $204K as of Q1 2026.
  • XTX Topco sold 58,012 Eledon Pharmaceuticals shares in Q1 2026, an estimated $137K.
  • Eledon Pharmaceuticals made up ﹤0.01% of XTX Topco's portfolio in Q1 2026, its #2833 holding.
  • XTX Topco first reported a position in Eledon Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • 121 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q1 2026.

Based on XTX Topco's 13F filing for Q1 2026, filed 15 May 2026.